STM JOURNALS

International Journal of
Antibiotics

https://journals.stmjournals.com/ijab

ISSN: 2584-2986
Volume 3, Issue 1, 2026
January–June
DOI (Journal): 10.37591/IJAB

Review IJAB

The Dual Crisis: Antibiotic Resistance and the Discovery Void – A Review of Novel Therapeutic Strategies and Non-Traditional Approaches

Priyanshu Upadhyay[1,*], Ankit Maurya[1], Anand Prakash[2]

Abstract

The global rise of antimicrobial resistance (AMR) has emerged as one of the most critical public health challenges of the 21st century, threatening to undermine decades of therapeutic success and rendering conventional antibiotic regimens increasingly ineffective. Parallel to the escalating resistance rates is a profound "discovery void," characterized by a steep decline in the development of new antibiotic classes since the late 20th century. Together, these two interconnected crises create a dual burden that significantly restricts treatment options and increases morbidity, mortality, and economic costs worldwide. This review provides a comprehensive evaluation of the underlying drivers of antibiotic resistance, the stagnation of antimicrobial innovation, and the urgent need for novel therapeutics that bypass the limitations of conventional drug discovery. Further, this paper highlights emerging non-traditional approaches – including bacteriophage therapy, antimicrobial peptides, CRISPR-based antimicrobials, nanoparticles, host-directed therapies, microbiome modulation, and anti-virulence strategies – that offer promising avenues to combat resistant pathogens without accelerating selective pressure. A detailed analysis of technological innovations such as AI-driven drug discovery, metagenomic mining, synthetic biology, and immunotherapeutic advancements is also presented. By integrating classical and alternative strategies, this review underscores the importance of a multifaceted approach to addressing the dual crisis and revitalizing the antibiotic development pipeline for sustainable global health.

Keywords: Anti-virulence strategies, antibiotic resistance, antimicrobial peptides, antimicrobial resistance (amr), bacteriophage therapy, crispr antimicrobials, discovery void, drug discovery, host-directed therapy, microbiome modulation, nanoparticle therapeutics, non-traditional antimicrobials, novel therapeutics, synthetic biology

INTRODUCTION OVERVIEW

Antibiotic resistance has become a major global health emergency, compromising the effectiveness of standard therapies and leading to prolonged illness, treatment failures, and increased mortality. According to global surveillance studies, resistant pathogens are responsible for millions of deaths annually, and the burden is projected to rise drastically if immediate interventions are not implemented. The widespread misuse of antibiotics in clinical, veterinary, and agricultural settings has accelerated the emergence of resistant strains, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) organisms [1–2].

In parallel, the pharmaceutical pipeline for new antibiotics has dramatically slowed. Since the "golden era" of antibiotic discovery (1940–1960),

***Author for Correspondence**
Priyanshu Upadhyay
E-mail: priyanshu.upadhyay651@gmail.com

[1]Postgraduate Student, Department of Pharmacy (M.Pharm.), P.K. University, Shivpuri, Madhya Pradesh, India
[2]Postgraduate Student, Department of Pharmacy (M.Pharm.), S.N. College of Pharmacy, Jaunpur, Uttar Pradesh, India

Received Date: January 28, 2026
Accepted Date: January 30, 2026
Published Date: January 31, 2026

Citation: Priyanshu Upadhyay, Ankit Maurya, Anand Prakash. The Dual Crisis: Antibiotic Resistance and the Discovery Void – A Review of Novel Therapeutic Strategies and Non-Traditional Approaches. International Journal of Antibiotics. 2026; 3(1): 47–65p.

no major novel classes have been successfully introduced into clinical practice in recent decades, leading to a profound *discovery void*. High development costs, rapid emergence of resistance, and low profitability have discouraged major pharmaceutical companies from investing in antibiotic R&D. Consequently, clinicians are left with dwindling treatment options, especially for infections caused by ESKAPE pathogens – *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,* and *Enterobacter* species.

This dual crisis – rising resistance and insufficient discovery – demands innovative and multidisciplinary solutions. Understanding the origins, mechanisms, and consequences of this crisis is essential for designing next-generation therapeutics and sustainable antimicrobial strategies (Table 1) [3–5].

Table 1. Comparison of antibiotic resistance vs. antibiotic discovery void.

Parameter	Antibiotic resistance	Discovery void
Primary cause	Overuse, misuse, genetic adaptation	Limited R&D investment, scientific saturation.
Clinical impact	Increased morbidity, mortality, failures	Shortage of new therapeutic options.
Evolution rate	Fast (within years)	Very slow (few new classes since 1990s).
Economic burden	Huge due to longer treatments	High development cost discourages companies.
Public health risk	Immediate and escalating	Long-term threat to treatment sustainability

INTRODUCTION: DRIVERS, MECHANISMS, AND GLOBAL IMPACT OF ANTIBIOTIC RESISTANCE

Antibiotic resistance is a multifactorial and dynamic phenomenon driven by biological, clinical, environmental, and socio-economic factors. These drivers act synergistically to accelerate the spread of resistant determinants across ecosystems – clinical, agricultural, aquatic, and environmental. A comprehensive understanding of these drivers is essential for the formulation of targeted interventions [6–7].

Key Drivers of Antibiotic Resistance Factors

Misuse and General Overuse in Human Medicine

Inappropriate prescription practices, self-medication, incomplete treatment courses, and non-compliance contribute significantly to resistance. In many developing countries, antibiotics are available over-the-counter, leading to indiscriminate use even for viral infections such as the common cold [8].

Veterinary and Comprehensive Agricultural Overuse

Antibiotics used as growth promoters in livestock, poultry, and aquaculture exert selective pressure, favoring resistant bacteria that can transfer to humans via:

- Contaminated food products.
- Environmental pathways (soil, water).
- Direct occupational exposure.

Environmental Contamination Sources

Pharmaceutical effluents, hospital wastewater, and agricultural runoff introduce antibiotic residues and resistant genes into natural environments. This promotes the proliferation of environmental resistomes in rivers, lakes, and soil [9].

Global Travel and Rapid Urbanization

Rapid movement of people, animals, and goods facilitates the dissemination of resistant strains across borders.

Mechanisms of Antibiotic Resistance

Bacteria employ diverse strategies to overcome antibiotic pressure. These mechanisms may be:

- Intrinsic → natural characteristics of the bacteria.
- Acquired → mutations or horizontal gene transfer (HGT).

Enzymatic Drug Target Inactivation

Bacteria produce enzymes that degrade or modify antibiotics examples:

- β-lactamases.
- Carbapenemases.
- Aminoglycoside-modifying enzymes.

Target Modification

Alteration of drug-binding sites prevents antibiotic attachment – for example, mutation of DNA gyrase (fluoroquinolone resistance) [10–12].

Reduced Cellular Permeability

Modifications in porin channels (e.g., in *Pseudomonas aeruginosa*) limit antibiotic entry.

Active Efflux Pumps

Efflux systems expel antibiotics from the cell. Families include:

- Major Facilitator Superfamily (MFS).
- ATP-binding cassette (ABC) transporters.
- Resistance-nodulation-division (RND) systems.

Biofilm Formation

Biofilms create a protective matrix that reduces drug penetration and increases tolerance (Table 2).

Table 2. Classification of antibiotic resistance mechanisms.

Mechanism	Description	Examples
Enzymatic degradation	Enzymes destroy or modify antibiotics	β-lactamase, NDM-1 enzyme.
Target modification	Mutation or methylation of target sites	Altered PBPs, rRNA methylation.
Permeability changes	Downregulation/mutation of porins	OprD mutation in *P. aeruginosa.*
Efflux pumps	Transporters remove drugs from cells	TetA, AcrAB-TolC.
Biofilms	Complex microbial communities with high tolerance	*Staphylococcus* spp., *Klebsiella* spp.

The Broad Global Impact of Antibiotic Resistance

Antibiotic resistance poses severe clinical, economic, and societal challenges.

General Clinical Burden

- Prolonged illness duration.
- Increased hospitalization.
- Higher treatment failure rates.
- Surge in MDR, XDR, and PDR strains.

Adverse Economic Consequences

- Increased cost of prolonged treatment.
- Additional diagnostics and supportive care.
- Loss of productivity.
- Economic pressure on healthcare systems.

Societal and General Public Health Implications

- Spread of untreatable infections.
- Compromised success of modern medical procedures:

- Organ transplants.
- Chemotherapy.
- Major surgeries.

ANTIBIOTIC DISCOVERY VOID: HISTORICAL CONTEXT AND THE DECLINE IN NEW ANTIBIOTIC CLASSES EXPLORED

The term *"antibiotic discovery void"* refers to the prolonged stagnation in the development of novel antibiotic classes since the late 20th century. Despite the growing burden of antimicrobial resistance, the rate of discovery of new antibiotics has sharply declined after the "Golden Era" (1940–1960), during which most major antibiotic classes – β-lactams, tetracyclines, macrolides, aminoglycosides – were discovered. From the 1980s onward, only a handful of new classes have reached clinical use, creating a critical innovation gap [13–16].

The Golden Era vs. the Modern Era of Antibiotic Discovery Progress

The Significant Golden Era (1940–1960)

This period witnessed an explosion of antibiotic discovery, largely driven by:

- Natural product screening from *Streptomyces* and soil microbes.
- Implementation of fermentation technologies.
- Simplified regulatory frameworks.
- High pharmaceutical investment [17].

General Transition to the Modern Era (1970s–1990s)

During this time:

- Most easily accessible natural scaffolds were already exhausted.
- Redundant screening produced repeated rediscoveries.
- Pharmaceutical interests shifted towards chronic disease therapeutics.
- Increased regulatory and development complexity discouraged antibiotic R&D [18].

The Post-2000 Period: Almost No New Classes

Despite rising AMR, the development pipeline shrank because of:

- Low return on investment.
- Rapid resistance to new molecules.
- High failure rates in clinical trials (Table 3).

Table 3. Timeline of major antibiotic class discoveries.

Antibiotic class	Decade of discovery	Source/origin	Present resistance status
Penicillins	1940s	*Penicillium* spp.	Widespread resistance.
Aminoglycosides	1940s	*Streptomyces* spp.	Increasing MDR resistance.
Tetracyclines	1950s	Soil actinomycetes	Highly resistant pathogens.
Macrolides	1950s	Actinomycetes	High resistance in *Streptococcus.*
Cephalosporins	1960s	Marine fungi	ESBL-producing strains.
Carbapenems	1980s	Semi-synthetic	Carbapenemase emergence.
Oxazolidinones (Linezolid)	1990s	Synthetic	Emerging resistance.

Why the Discovery Pipeline Has Become Stagnant Today

The stagnation of antibiotic innovation is driven by a combination of scientific, economic, regulatory, and ecological factors.

Scientific Barriers

Exhaustion of Natural Product Space

Traditional screening methods repeatedly rediscover similar scaffolds from soil microbes, reducing novelty.

Difficulty in Targeting Gram-Negative Bacteria

Gram-negative pathogens possess:

- An outer membrane as a permeability barrier.
- Efficient efflux pumps.
- Dense lipopolysaccharide (LPS) layers.

This makes drug penetration challenging.

Rapid Resistance Evolution

Antibiotics with single protein targets are prone to quick resistance development, reducing their clinical lifespan [19–24].

Global Economic Limitations

Pharmaceutical companies increasingly prioritize high-profit therapeutics, such as:

- Oncology.
- Cardiology.
- Chronic diseases.
- Lifestyle disorders.

Since antibiotics are:

- Short-duration treatments.
- Priced low in many regions.
- Restricted through stewardship their financial return is lower than other drug categories (Table 4).

Table 4. Comparison of antibiotic profitability vs. other drug types.

Parameter	Antibiotics	Chronic disease drugs
Treatment duration	5–14 days	Lifelong.
Sales potential	Low	Very high.
Stewardship restrictions	High	Minimal.
Profit margin	Low	High.
Investment interest	Declining	Increasing.

Complex Regulatory Challenges

Modern regulatory frameworks demand:

- Large-scale clinical trials.
- Robust safety/toxicity assessment.
- Extensive post-marketing surveillance.

These factors increase development time and cost.

Ecological and Epidemiological Challenges

Antibiotics disrupt microbiomes and accelerate resistance. Regulatory authorities thus emphasize caution, making approval harder.

The Current Global Status of the Antibiotic Discovery Pipeline

Current antibiotic pipelines contain mainly:

- Variants of existing classes.
- Modifications of old scaffolds.
- Combination therapies.
- Few truly *novel* classes.

Only a limited number of candidates have new mechanisms of action (MOAs). Moreover, most new approvals are modifications rather than groundbreaking agents (Table 5).

Table 5. Global antibiotic pipeline (summary classification).

Category	% of Pipeline	Characteristics
New chemical entities (old classes)	~70%	β-lactams, tetracycline derivatives.
Truly novel classes	<10%	Very few (e.g., teixobactin candidates).
Non-traditional biologics	~15%	Phages, AMPs, antibodies.
Microbiome-targeted products	<5%	FMT-based therapies.

NOVEL THERAPEUTIC STRATEGIES (PART I): BACTERIOPHAGE THERAPY AND PHAGE-BASED TECHNOLOGIES REVIEWED

As conventional antibiotics continue to lose effectiveness, bacteriophages (phages) – viruses that specifically infect bacteria – have re-emerged as a promising class of biological antimicrobials. Phages offer species- or strain-specific activity, excellent safety profiles, the ability to self-replicate at the site of infection, and a reduced likelihood of disturbing host microbiota. Once overshadowed by antibiotics in the West, phage therapy is experiencing a resurgence due to mounting AMR rates and advancements in genomics, bioengineering, and synthetic biology [25–26].

Bacteriophage Biology and Mechanism of Action

Phages are viruses that infect bacteria through highly specific receptor–ligand interactions. Their replication cycles can be:

- Lytic (virulent) → desirable for therapy.
- Lysogenic (temperate) → avoided to prevent horizontal gene transfer.

The Lytic Cycle (Therapeutic Mode)

Steps:

- *Adsorption:*
  - Phage binds to bacterial surface receptors (e.g., LPS, pili, porins).
- *Penetration:*
  - Viral genetic material is injected into the bacterial cytoplasm.
- *Replication and Assembly:*
  - Host cellular machinery produces viral proteins and new virions.
- *Cell Lysis:*
  - Phage-encoded endolysins and holins rupture the bacterium, releasing progeny.

Advantages of Bacteriophage Therapy

High Specificity

Phages target only pathogenic bacteria without harming beneficial microbiota.

Self-Amplification at Infection Site

Phages replicate only in the presence of their bacterial host, increasing their therapeutic concentration automatically [27–28].

Effective Against Biofilms

Phages produce depolymerases that degrade biofilm matrices, allowing deeper penetration.

Resistance Development Patterns

While bacteria can develop phage resistance, co-evolving phage populations can counter this.

Synergy with Antibiotics

Phages and antibiotics together exhibit "phage-antibiotic synergy" (PAS), lowering bacterial load more effectively (Table 6).

Table 6. Comparison of antibiotics vs. bacteriophage therapy.

Parameter	Antibiotics	Phage therapy
Target specificity	Broad	Highly specific.
Effect on microbiota	Significant disruption	Minimal or none.
Self-replication	No	Yes.
Efficacy against biofilms	Limited	Strong (via depolymerases).
Resistance evolution	Very fast	Counteracted by phage evolution.
Toxicity profile	Drug-dependent	Generally minimal.

Clinical Applications for Phage Therapy

Phages have demonstrated efficacy against multiple MDR pathogens, including:

- *Acinetobacter baumannii*.
- *Pseudomonas aeruginosa*.
- MRSA.
- ESBL/carbapenemase-producing Enterobacteriaceae.
- Klebsiella pneumoniae biofilms.

Clinical routes include:

- Topical application.
- Oral formulations.
- Intravenous (IV) therapy.
- Inhalation for pulmonary infections.

Compassionate Use and Case Studies

Recent clinical successes include:

- Treatment of MDR *A. baumannii* septicemia (UCSF case study).
- Resolution of *P. aeruginosa* lung infection in cystic fibrosis patient.
- Successful use in diabetic foot ulcers and burn wound infections [29].

Phage Engineering and Synthetic Phage Platforms

Advancements in molecular biology have enabled engineering of phages to:

- Expand host range.
- Enhance lytic potency.
- Deliver CRISPR payloads.
- Overcome bacterial anti-phage systems.

CRISPR-Enhanced Phages

CRISPR-Cas systems can be packaged inside phages, allowing precision killing of bacteria by:

- Targeting essential genes.
- Targeting resistance genes.
- Removing plasmids carrying AMR determinants.

Chimeric Phages

Tailored phages engineered using:

- Modified receptor-binding proteins.
- Hybrid lytic enzymes.
- Synthetic capsid components.

These broaden host range and improve stability.

Phage-Enzyme Therapy (Endolysins and Depolymerases)

Phage-derived enzymes are being explored as stand-alone antimicrobials.

Endolysins
- Hydrolyze bacterial cell walls.
- Highly effective against Gram-positive bacteria.
- It can be engineered to target Gram-negative outer membrane.

Depolymerases
- Degrade biofilm polysaccharides.
- Useful for catheter-related infections, dental plaques, and chronic wounds (Table 7) [30].

Table 7. Mechanistic classification of phage-derived enzymes.

Enzyme type	Target	Application
Endolysins	Peptidoglycan	MRSA, *Enterococcus*, skin infections.
Depolymerases	Biofilm polysaccharides	Biofilm clearance, catheter infections.
Holins	Cell membrane perforation	Phage-assisted lytic cycles.
Virion-associated lysins	Cell wall during entry	Gram-positive pathogens.

Challenges and Limitations of Phage Therapy

Despite its promise, phage therapy faces hurdles.

Regulatory Complexity

Phages are biological entities with genome variability; standardization is difficult.

Narrow Host Range

While specificity is an advantage, it also requires accurate strain-level diagnostics.

Phage Neutralization by Immune System

Repeated systemic administration may induce anti-phage antibodies.

Limited Global Manufacturing Capacity

Current GMP-certified phage production facilities are insufficient.

NOVEL THERAPEUTIC STRATEGIES (PART II): ANTIMICROBIAL PEPTIDES, NANOPARTICLE THERAPEUTICS, AND ANTI-VIRULENCE APPROACHES DISCUSSED

The escalating threat of AMR necessitates the exploration of innovative therapeutics that act through mechanisms distinct from traditional antibiotics. Among these, *antimicrobial peptides (AMPs)*, *nanoparticle-based antimicrobials*, and *anti-virulence agents* represent some of the most promising non-traditional strategies.

These therapeutics circumvent conventional resistance mechanisms, exhibit multi-targeted modes of action, and are less likely to induce widespread selective pressure. This segment provides an in-depth analysis of their biological basis, therapeutic potential, and challenges [31–32].

Antimicrobial Peptides (AMPs)

AMPs are short, cationic, amphipathic peptides produced by various organisms as part of innate immunity. These peptides exhibit broad-spectrum activity against bacteria, viruses, fungi, and protozoa.

Primary Mechanisms of Action of AMPs

AMPs interact primarily with microbial membranes via:
- Electrostatic attraction between cationic AMPs and negatively charged bacterial membranes.
- Membrane insertion is due to amphipathic nature.
- Pore formation or membrane disruption.
- Intracellular targeting (DNA, enzymes).

Primary models of AMP action:

- Barrel-stave model.
- Carpet model.
- Toroidal pore model.

Therapeutic Applications of AMPs

AMPs demonstrate strong efficacy against:

- MDR Gram-negative bacteria (*A. baumannii, P. aeruginosa*).
- MRSA.
- Biofilms.
- Fungal pathogens (Candida spp.)

Examples of clinically relevant AMPs:

- *LL-37* – Human cathelicidin.
- *Nisin* – lantibiotic used in food preservation.
- *Daptomycin* – cyclic lipopeptide used clinically.
- *Colistin* – last-resort polymyxin (Table 8).

Table 8. Comparison of natural vs. synthetic AMPs.

Parameter	Natural AMPs	Synthetic/engineered AMPs
Origin	Humans, animals, plants	Designed in silico.
Stability	Moderate	Enhanced stability possible.
Activity Spectrum	Narrow to moderate	Tunable (broad/narrow).
Toxicity	Generally low	Can be optimized.
Cost	Low-moderate	Higher production cost.

Advantages of AMPs

- Multi-target mechanisms reduce resistance development.
- Effective against dormant or slow-growing bacteria.
- Activity in biofilms.
- Immunomodulatory properties.

However, challenges include *poor stability*, *high production cost*, and potential *cytotoxicity* at elevated doses [33–34].

Nanoparticle-Based Antimicrobials

Nanotechnology offers a cutting-edge platform to overcome bacterial defenses. Nanoparticles (NPs) exhibit intrinsic antimicrobial activity and serve as delivery systems for antibiotics, peptides, or genetic material [35].

Types of Antimicrobial Nanoparticles

Metal/Metal Oxide Nanoparticles

- Silver, gold, zinc oxide, titanium dioxide.

Carbon-Based Nanoparticles

- Graphene oxide.
- Carbon nanotubes.

Polymeric Nanoparticles

- PLGA.
- Chitosan.

Lipid-Based Nanoparticles
- Liposomes.
- Solid lipid nanoparticles.

Mechanisms of Action of Nanoparticles

Nanoparticles kill bacteria via:
- Generation of *reactive oxygen species (ROS).*
- Membrane disruption.
- Metal ion release.
- DNA and protein damage.
- Inhibition of metabolic pathways.
- Drug delivery enhancement.

Advantages of Nanoparticle Therapies
- Overcome efflux pumps.
- Penetrate biofilms.
- Multi-targeted killing.
- Can bypass resistance pathways.
- Controlled drug release.
- Reduced systemic toxicity (Table 9).

Table 9. Commonly investigated antimicrobial nanoparticles.

Nanoparticle type	Mechanism	Therapeutic applications
Silver NPs	ROS, membrane disruption	Wound healing, coatings.
Gold NPs	Photothermal killing	Targeted therapy.
ZnO NPs	ROS generation	Topical formulations.
Chitosan NPs	Membrane disruption	Oral/gastrointestinal infections.
Liposomes	Drug delivery	Targeted antibiotic therapy.

Anti-Virulence Therapeutics

Unlike antibiotics, anti-virulence therapies neutralize bacterial pathogenicity without killing the organism, thereby *minimizing selective pressure*.

Target Classes in Anti-Virulence Strategies
- Toxins (e.g., diphtheria toxin).
- Quorum sensing pathways.
- Adhesion factors.
- Secretion systems (Type III, Type VI).
- Biofilm formation pathways.

Quorum Sensing Inhibitors (QSIs)

QSIs disrupt bacterial communication networks and prevent coordinated virulence expression.
- AHL analogs for Gram-negative bacteria.
- AI-2 inhibitors for interspecies communication.
- Peptide signal blockers (Gram-positive bacteria).

Advantages of Anti-Virulence Approaches
- Low selection pressure.
- Preservation of beneficial microbiota.
- Potential synergy with antibiotics.
- Reduced resistance evolution (Table 10).

Table 10. Comparison of anti-virulence therapies vs. antibiotics.

Parameter	Anti-virulence therapy	Antibiotics
Mode of action	Blocks pathogenicity	Kills bacteria.
Selective pressure	Very low	High.
Resistance risk	Low	High.
Impact on microbiome	Minimal	Significant.
Best use	Combination therapy	Alone or combined.

NOVEL THERAPEUTIC STRATEGIES (PART III): HOST-DIRECTED THERAPIES, MICROBIOME MODULATION, AND CRISPR-BASED ANTIMICROBIALS INCLUDED

Beyond directly targeting pathogenic bacteria, modern strategies increasingly focus on strengthening host defenses, altering microbial ecosystems, or using gene-editing tools for precision antibacterial action. These approaches reduce reliance on traditional antibiotics and avoid selective pressure that accelerates resistance.

Host-Directed Therapies (HDTs)

Host-directed therapies aim to enhance the host immune response, modulate inflammation, or disrupt host–pathogen interactions. HDTs do not directly target bacteria; instead, they empower the host to eliminate infection naturally [17–18].

Mechanisms of Host-Directed Therapies

Enhancing Immune Response

- Activation of macrophages.
- Induction of autophagy.
- Improved antigen presentation.
- Stimulation of innate pathways (TLRs, NLRs)

Blocking Host Factors Essential for Infection

Examples:

- Inhibiting host receptors are used for bacterial attachment.
- Modulating iron availability (nutritional immunity).

Regulating Inflammation

Preventing excessive inflammation reduces tissue damage in chronic infections (Table 11).

Table 11. Categories of host-directed therapies.

Type of HDT	Mechanism	Example candidates
Immunomodulators	Boost innate immunity	IFN-γ, IL-2.
Autophagy inducers	Enhance intracellular killing	Rapamycin.
Nutritional immunity modulators	Restrict metal ions	Iron chelators.
Host receptor blockers	Prevent pathogen entry	CCR5 antagonists.
Anti-inflammatory agents	Reduce tissue pathology	Corticosteroids.

HDTs in Tuberculosis and MDR Infections

Host-directed therapy is especially valuable for diseases like:

- Tuberculosis (TB) – intracellular pathogen.
- MDR/XDR TB – limited antibiotic options.

Agents such as metformin, statins, and vitamin D analogs enhance macrophage-mediated clearance.

Microbiome Modulation as an Antimicrobial Strategy

The human microbiome is essential for immune regulation, metabolic health, and colonization resistance against pathogens. Dysbiosis increases susceptibility to infections such as *Clostridioides difficile*, MRSA, and VRE.

Microbiome modulation restores ecological balance and suppresses pathogenic growth without antibiotics [20–21].

Key Methods of Microbiome Modulation

Probiotics

Live beneficial bacteria (e.g., *Lactobacillus*, *Bifidobacterium*) competitively inhibit pathogens.

Prebiotics

Non-digestible substrates (e.g., inulin) promote growth of healthy microbiota.

Synbiotics

Combination of probiotics and prebiotics.

Microbiota-Targeted Drugs

Agents that selectively modulate microbial metabolic pathways.

Fecal Microbiota Transplantation (FMT)

Transfer of stool microbiota from a healthy donor to restore community balance.

Applications for Microbiome-Based Therapeutics

- Recurrent *C. difficile* infection (CDI) – highest success with FMT.
- Prevention of antibiotic-associated diarrhea.
- Reducing colonization of MDR pathogens in the gut.
- Correction of dysbiosis to support immune homeostasis (Table 12).

Table 12. Microbiome therapeutic methods and their targets.

Strategy	Biological target	Example use
Probiotics	Gut pathogens	Preventing AAD, restoring gut flora.
Prebiotics	Beneficial flora	Improving SCFA production.
FMT	Entire microbiome	Treating recurrent CDI.
Synbiotics	Gut colonization	Neonatal gut development.
Microbiota inhibitors	Harmful bacteria	Controlling MDR colonization.

CRISPR-Based Antimicrobials

CRISPR-Cas systems, originally bacterial immune tools, have emerged as powerful programmable weapons for precise bacterial targeting. Unlike antibiotics, CRISPR can selectively eliminate strains or plasmids without affecting beneficial microbes [25].

Basic Mechanisms of CRISPR Antimicrobials

CRISPR-based antimicrobials rely on:

- Guide RNA (gRNA) targeting specific DNA sequences.
- Cas nucleases (e.g., Cas9) causing double-strand breaks.
- Cargo delivery via phages, plasmids, or nanoparticles.

Targets include:

- Essential bacterial genes.
- Resistance genes (e.g., NDM-1, mcr-1).
- Virulence genes.

Advantages of CRISPR Antimicrobials

- Strain-specific targeting.

- Elimination of plasmid-borne resistance genes.
- Minimal disruption to microbiomes.
- Ability to re-engineer phages for delivery.
- Reduced risk of resistance development.

Delivery Systems for CRISPR-Based Antimicrobials

Major delivery platforms include:

- Engineered bacteriophages.
- Conjugative plasmids.
- Nanoparticles.
- Lipid vesicles (Table 13).

Table 13. CRISPR antimicrobial platforms and their pros/cons.

Delivery method	Advantages	Limitations
Engineered phages	Natural targeting ability	Immune clearance.
Conjugative plasmids	Stable delivery	Limited host range.
Nanoparticles	Safe and versatile	Lower delivery efficiency.
Lipid carriers	Biocompatible	Short half-life.

Limitations and Challenges of CRISPR Antimicrobials Today

- Delivery efficiency remains a major hurdle.
- Mutation at target sites may reduce effectiveness.
- Immune responses against CRISPR proteins.
- Ethical and regulatory concerns.
- Risk of off-target DNA cleavage.

NOVEL DIAGNOSTICS AND RAPID DETECTION SYSTEMS: STRENGTHENING SURVEILLANCE AND STEWARDSHIP SYSTEMS

Effective management of antimicrobial resistance (AMR) requires not only new therapeutics but also *timely and precise diagnostic tools*. Rapid diagnostics enable clinicians to identify pathogens early, differentiate between bacterial and viral infections, and select appropriate therapies – reducing unnecessary antibiotic use. Advanced surveillance systems track resistance trends, guide stewardship programs, and support outbreak control.

The Global Importance of Rapid Diagnostics in Combating AMR

Traditional microbiological methods (culture, biochemical tests) require *24–72 hours*, delaying targeted therapy. This often leads to empirical broad-spectrum antibiotic use, driving selective pressure [29].

Modern rapid diagnostic technologies aim to:

- Reduce time-to-diagnosis.
- Identify pathogens and resistance determinants.
- Enable personalized, narrow-spectrum therapy.
- Strengthen infection control.
- Reduce hospital stay and cost.

Categories of Novel Diagnostic Technologies

Molecular Diagnostics

PCR-Based Assays

- Detect specific pathogens and resistance genes.
- High sensitivity and specificity.

Multiplex PCR Panels
- Simultaneously detect multiple pathogens (e.g., pneumonia, sepsis panels).

Next-Generation Sequencing (NGS)
- Whole-genome sequencing (WGS).
- Metagenomic sequencing.
- Useful for outbreak tracking and AMR gene discovery.

Immunodiagnostics

Use antigen–antibody interactions for detection.

Examples
- Lateral flow assays (rapid tests).
- ELISA-based pathogen detection.

Biosensor Technologies

Biosensors integrate biological recognition elements with signal transducers for *real-time pathogen detection* [30].

Types
- Electrochemical biosensors.
- Optical biosensors.
- Piezoelectric sensors.

CRISPR-Based Diagnostics

CRISPR-Cas systems such as Cas12 and Cas13 are used for nucleic acid detection with extremely high sensitivity.

Examples
- SHERLOCK.
- DETECTR.

These can detect AMR genes like *blaNDM*, *mcr-1*, *vanA*, etc.

Compact Microfluidic Lab-on-a-Chip Systems

Microfluidic devices integrate sample preparation, amplification, and detection into a compact system.

Advantages
- Low sample volume.
- Rapid processing.
- Portable and POC-friendly (Table 14).

Table 14. Overview of novel diagnostic platforms.

Diagnostic type	Speed	Target	Advantages
PCR assays	Hours	DNA/RNA	High accuracy.
NGS	Days–hours	Genome-level	Detailed AMR profiling.
Immunoassays	Minutes	Antigens	Simple POC tests.
CRISPR diagnostics	Minutes–hours	Nucleic acids	Ultra-sensitive.
Biosensors	Seconds–minutes	Biomarkers	Reusable and real-time.
Microfluidics	Minutes	Mixed	Portable, integrated.

Rapid Phenotypic Susceptibility Testing

Novel phenotypic tools detect bacterial growth inhibition faster than conventional culture-based susceptibility tests.

Examples

- Microfluidic-based antibiotic susceptibility assays.
- Flow cytometry for viability assessment.
- Colorimetric metabolic assays.
- Impedance-based growth monitoring.

These systems can provide MIC (Minimum Inhibitory Concentration) results within *2–6 hours*.

Point-of-Care (POC) Technologies

POC devices are essential in settings lacking advanced laboratory infrastructure.

Ideal POC diagnostic characteristics (ASSURED criteria):

- Affordable.
- Sensitive.
- Specific.
- User-friendly.
- Rapid.
- Equipment-free.
- Deliverable to end-users.

Examples of POC Devices

- Rapid strep test.
- MRSA nasal swabs.
- UTI dipsticks.
- CRISPR lateral flow strips.
- Portable PCR systems.

AMR Surveillance and Global Monitoring Systems

Effective surveillance is crucial for tracking resistance trends, informing policy, and guiding stewardship.

Key Global Surveillance Systems

- GLASS (Global Antimicrobial Resistance Surveillance System) – WHO.
- EARS-Net – European AMR surveillance.
- NARMS – US system monitoring antimicrobial resistance in foodborne pathogens.
- India's AMRSN (AMR Surveillance Network) (Table 15).

Table 15. Major AMR surveillance systems and their roles.

Surveillance system	Region	Key roles
GLASS	Global	Standardized AMR data collection.
EARS-Net	Europe	Resistance trends in hospitals.
NARMS	USA	Foodborne pathogen monitoring.
AMRSN (India)	India	National-level pathogen tracking.

Major Challenges in Implementing Novel Diagnostics

- High initial cost.

- Need for trained personnel.
- Limited availability in rural/low-resource settings.
- Data management and integration barriers.
- Regulatory requirements for POC diagnostics.
- Risk of overdiagnosis if improperly used.

FUTURE PERSPECTIVES AND INTEGRATED STRATEGIES FOR OVERCOMING THE DUAL CRISIS ANALYZED

Addressing the dual crisis of antimicrobial resistance (AMR) and the antibiotic discovery void requires coordinated global action, sustained innovation, and multidisciplinary collaboration. Future strategies must integrate therapeutic, diagnostic, ecological, and policy-driven approaches to achieve lasting impact [36].

Integrating Traditional and Non-Traditional Therapies

The future of antimicrobial treatment lies in combining conventional antibiotics with emerging modalities such as:

- Bacteriophages.
- Antimicrobial peptides.
- Nanoparticles.
- Immunotherapies.
- CRISPR-based antimicrobials.
- Microbiome engineering.
- Synthetic biology platforms.

Integrated Therapeutic Strategies May Include

- Phage–antibiotic synergy (PAS).
- AMP–nanoparticle hybrid formulations.
- CRISPR–phage combined delivery systems.
- Vaccine + monoclonal antibody prophylaxis.
- Host-directed therapy + conventional antibiotics.

These combinations target bacteria on multiple fronts, reducing the probability of resistance development.

Future Trends in Antibiotic Discovery

AI-Enhanced Molecular Design

Deep learning algorithms will continuously generate and optimize novel antimicrobial structures.

Digital Bioprospecting

Metagenomic mining of extreme environments (deep sea, glaciers, deserts) is expected to yield unique drug scaffolds.

Next-Generation Synthetic Biology

Designer microbes will serve as factories for on-demand antibiotic production.

Personalized Antimicrobial Therapy

Genomic-guided treatment will match therapies to patient-specific pathogens.

Targeting Persistence and Tolerance

Drugs designed specifically to eliminate persisters and biofilm-associated bacteria (Table 16).

Table 16. Predicted innovations in AMR management over the next decade.

Innovation area	Expected developments
AI-driven drugs	Rapid de novo molecule generation.
Phage therapy	Customized phage cocktails.
Microbiome therapies	Engineered gut microbiota.
Vaccines	Pan-bacterial or multi-antigen vaccines.
CRISPR antimicrobials	Gene-specific pathogen eradication.
Diagnostics	Ultra-rapid genomic tests.

Strengthening One Health Surveillance Networks

Future AMR monitoring systems will integrate:

- Human clinical data.
- Veterinary diagnostics.
- Environmental metagenomics.
- Wastewater-based epidemiology.

Key Components

- Cloud-based data platforms.
- Real-time genomic surveillance.
- Predictive AI models for resistance spread.
- Global coordination across nations

Policy and Economic Reforms: The Road Ahead Explored

Global health authorities must implement far-reaching policy changes:

Economic Incentives

- Market entry awards ($1–2 billion per new antibiotic).
- Tax incentives for R&D.
- Public–private partnerships.

Strengthening Regulations

- Prevent OTC antibiotic sales.
- Enforce strict agricultural antibiotic policies.
- Regulate pharmaceutical waste disposal.

Education and Awareness

- Public campaigns promote rational antibiotic use.
- Training for healthcare professionals.
- Incorporation of AMR content in medical/pharmacy curricula.

Persistent Challenges That Will Remain

Despite advancements, certain challenges will remain:

- Rapid bacterial evolution.
- Geographical inequity in healthcare access.
- Limited global compliance.
- High development costs for new technologies.
- Bioethical concerns with engineered organisms.
- Increasing environmental reservoirs of AMR genes.

CONCLUSION

The dual crisis of *antibiotic resistance* and the *discovery void* represent a major threat to global health, modern medicine, and socioeconomic stability. Conventional antibiotics alone are insufficient to address this escalating challenge. A successful response requires a *multifaceted, integrated approach* combining:

- Traditional and novel therapeutics.
- Precision diagnostics.
- Ecological and microbiome-based interventions.
- Robust stewardship programs.
- Policy reforms and global cooperation.
- A unified One Health strategy.

The future of antimicrobial innovation will rely on emerging fields – including AI-driven discovery, synthetic biology, engineered phages, microbiome manipulation, and immunotherapies – to restore the efficacy of infectious disease treatments. Only through coordinated scientific, clinical, and public health action can the world prevent a post-antibiotic era and ensure sustainable management of infections in the decades ahead.

REFERENCES

1. World Health Organization. Global action plan on antimicrobial resistance. Geneva: WHO Press; 2015.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta (GA): U.S. Department of Health and Human Services; 2019.
3. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. London: Review on Antimicrobial Resistance, UK Government; 2016.
4. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA: Annual epidemiological report 2023. Stockholm: ECDC; 2024.
5. Indian Council of Medical Research. Annual report on antimicrobial resistance surveillance and research network. New Delhi: ICMR; 2022.
6. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51. doi: 10.1038/nrmicro3380.
7. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2):VMBF-0016-2015. doi: 10.1128/microbiolspec.VMBF-0016-2015.
8. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance: The need for coordinated global solutions. Lancet Infect Dis. 2013;13(12):1057–1098. doi: 10.1016/S1473-3099(13)70318-9.
9. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A multifaceted global challenge. Pathog Glob Health. 2015;109(7):309–318. doi: 10.1179/2047773215Y.0000000030.
10. Rice LB. Mechanisms of resistance and clinical significance of resistance to β-lactams, glycopeptides and fluoroquinolones. Mayo Clin Proc. 2012;87(2):198–208. doi: 10.1016/j.mayocp.2011.12.003.
11. Brown ED, Wright GD. Antibacterial drug discovery in the era of resistance. Nature. 2016;529(7586):336–343. doi: 10.1038/nature17042.
12. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! Clin Infect Dis. 2009;48(1):1–12. doi: 10.1086/595011.
13. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov. 2013;12(5):371–387. doi: 10.1038/nrd3975.
14. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71–109. doi: 10.1128/CMR.00030-10.
15. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for resistant pathogens: Addressing the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29–40. doi: 10.1038/nrd2201.
16. Schooley RT, Biswas B, Gill JJ, et al. Development and application of personalized bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2017;61(7):e00954-17. doi: 10.1128/AAC.00954-17.
17. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage therapy for human bacterial infections: Principles and practice. Bacteriophage. 2011;1(2):66–85. doi: 10.4161/bact.1.2.15845.
18. Lin DM, Koskella B, Lin HC. Phage therapy as an alternative strategy in the era of multidrug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–173. doi: 10.4292/wjgpt.v8.i3.162.

19. Pirnay JP, Merabishvili M, Van Raemdonck H, et al. Quality and safety standards for sustainable bacteriophage therapy products. Pharm Res. 2015;32(7):2173–2179. doi: 10.1007/s11095-014-1617-7.
20. Hyman P. Bacteriophages and their application in phage therapy: Isolation, characterization and host range determination. Pharmaceutics. 2019;11(3):35. doi: 10.3390/pharmaceutics11030035.
21. Hancock REW, Sahl HG. Antimicrobial peptides and host defense peptides as novel therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–1557. doi: 10.1038/nbt1267.
22. Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: Biological functions and clinical potential. Nat Rev Drug Discov. 2020;19(5):311–332. doi: 10.1038/s41573-019-0058-8.
23. Rai M, Yadav A, Gade A. Silver nanoparticles as emerging antimicrobial agents. Biotechnol Adv. 2009;27(1):76–83. doi: 10.1016/j.biotechadv.2008.09.002.
24. Huh AJ, Kwon YJ. Nanoantibiotics: A new approach to combat infectious diseases using nanomaterials. Int J Nanomedicine. 2011;6:2993–3007. doi: 10.2147/IJN.S24693.
25. Hasan J, Crawford RJ, Ivanova EP. Antibacterial surfaces: Progress toward next-generation biomaterials. Trends Biotechnol. 2013;31(5):295–304. doi: 10.1016/j.tibtech.2013.01.017.
26. Bikard D, Euler CW, Jiang W, et al. Exploiting CRISPR-Cas systems to develop sequence-specific antimicrobials. Nat Biotechnol. 2014;32(11):1146–1150. doi: 10.1038/nbt.3043.
27. Citorik RJ, Mimee M, Lu TK. Sequence-specific antimicrobials using RNA-guided nucleases. Nat Biotechnol. 2014;32(11):1141–1145. doi: 10.1038/nbt.3011.
28. van Belkum A, Bachmann TT, et al. Development roadmap for antimicrobial susceptibility testing systems. Nat Rev Microbiol. 2019;17(1):51–62. doi: 10.1038/s41579-018-0098-9.
29. Caliendo AM, Gilbert DN, et al. Improved diagnostics for infectious diseases: Better tests, better patient care. Clin Infect Dis. 2013;57(Suppl 3):S139–S170. doi: 10.1093/cid/cit578.
30. Kwong JC, McCallum N, Sintchenko V, Howden BP. Whole-genome sequencing in antimicrobial resistance surveillance. Clin Infect Dis. 2015;61(7):1099–1106. doi: 10.1093/cid/civ450.
31. Gootenberg JS, Abudayyeh OO, Kellner MJ, et al. Multiplexed and portable nucleic acid detection using CRISPR-based technologies. Science. 2018;360(6387):439–444. doi: 10.1126/science.aaq0179.
32. Niemz A, Ferguson TM, Boyle DS. Point-of-care nucleic acid testing for infectious diseases. Trends Biotechnol. 2011;29(5):240–250. doi: 10.1016/j.tibtech.2011.01.007.
33. Dyar OJ, Huttner B, Schouten J, Pulcini C. Antimicrobial stewardship: Principles and practice. Clin Microbiol Infect. 2017;23(11):793–798. doi: 10.1016/j.cmi.2017.08.026.
34. Holmes AH, Moore LSP, Sundsfjord A, et al. Mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–187. doi: 10.1016/S0140-6736(15)00473-0.
35. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, animals and the environment. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140083. doi: 10.1098/rstb.2014.0083.
36. Robinson TP, Bu DP, Carrique-Mas J, et al. Antibiotic resistance as a major One Health challenge. Trans R Soc Trop Med Hyg. 2016;110(7):377–380. doi: 10.1093/trstmh/trw048.

